nodes	percent_of_prediction	percent_of_DWPC	metapath
Anagrelide—CYP1A2—Pazopanib—kidney cancer	0.101	0.436	CbGbCtD
Anagrelide—CYP1A2—Erlotinib—kidney cancer	0.072	0.311	CbGbCtD
Anagrelide—CYP1A2—Sorafenib—kidney cancer	0.0586	0.253	CbGbCtD
Anagrelide—PDE3A—cGMP effects—KCNMA1—kidney cancer	0.00251	0.125	CbGpPWpGaD
Anagrelide—PDE3A—Nitric oxide stimulates guanylate cyclase—KCNMA1—kidney cancer	0.00199	0.099	CbGpPWpGaD
Anagrelide—CYP1A2—Aflatoxin activation and detoxification—ACY1—kidney cancer	0.00114	0.0565	CbGpPWpGaD
Anagrelide—PDE3A—Platelet homeostasis—KCNMA1—kidney cancer	0.000777	0.0385	CbGpPWpGaD
Anagrelide—CYP1A2—Fatty Acid Omega Oxidation—ALDH1A1—kidney cancer	0.000716	0.0355	CbGpPWpGaD
Anagrelide—PDE3A—Platelet homeostasis—ITPR2—kidney cancer	0.00063	0.0313	CbGpPWpGaD
Anagrelide—CYP1A2—Aflatoxin B1 metabolism—GSTM1—kidney cancer	0.000519	0.0258	CbGpPWpGaD
Anagrelide—CYP1A2—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—kidney cancer	0.000443	0.022	CbGpPWpGaD
Anagrelide—CYP1A2—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—kidney cancer	0.000403	0.02	CbGpPWpGaD
Anagrelide—Hypertension—Paclitaxel—kidney cancer	0.000322	0.00043	CcSEcCtD
Anagrelide—Pruritus—Sunitinib—kidney cancer	0.000321	0.000429	CcSEcCtD
Anagrelide—Myalgia—Paclitaxel—kidney cancer	0.000318	0.000424	CcSEcCtD
Anagrelide—Arthralgia—Paclitaxel—kidney cancer	0.000318	0.000424	CcSEcCtD
Anagrelide—Chest pain—Paclitaxel—kidney cancer	0.000318	0.000424	CcSEcCtD
Anagrelide—Mediastinal disorder—Capecitabine—kidney cancer	0.000317	0.000424	CcSEcCtD
Anagrelide—Decreased appetite—Gemcitabine—kidney cancer	0.000316	0.000422	CcSEcCtD
Anagrelide—Chills—Capecitabine—kidney cancer	0.000316	0.000422	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000315	0.000422	CcSEcCtD
Anagrelide—Arrhythmia—Capecitabine—kidney cancer	0.000314	0.00042	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000314	0.00042	CcSEcCtD
Anagrelide—Discomfort—Paclitaxel—kidney cancer	0.000314	0.000419	CcSEcCtD
Anagrelide—Fatigue—Gemcitabine—kidney cancer	0.000314	0.000419	CcSEcCtD
Anagrelide—Gastrointestinal pain—Vincristine—kidney cancer	0.000313	0.000419	CcSEcCtD
Anagrelide—Dizziness—Sorafenib—kidney cancer	0.000311	0.000416	CcSEcCtD
Anagrelide—Constipation—Gemcitabine—kidney cancer	0.000311	0.000416	CcSEcCtD
Anagrelide—Pain—Gemcitabine—kidney cancer	0.000311	0.000416	CcSEcCtD
Anagrelide—Nausea—Erlotinib—kidney cancer	0.000311	0.000416	CcSEcCtD
Anagrelide—Alopecia—Capecitabine—kidney cancer	0.000311	0.000415	CcSEcCtD
Anagrelide—Dry mouth—Paclitaxel—kidney cancer	0.000311	0.000415	CcSEcCtD
Anagrelide—Diarrhoea—Sunitinib—kidney cancer	0.00031	0.000414	CcSEcCtD
Anagrelide—Asthenia—Dactinomycin—kidney cancer	0.000308	0.000411	CcSEcCtD
Anagrelide—CYP1A2—Tryptophan metabolism—ALDH1A1—kidney cancer	0.000308	0.0153	CbGpPWpGaD
Anagrelide—Confusional state—Paclitaxel—kidney cancer	0.000307	0.00041	CcSEcCtD
Anagrelide—Blood creatinine increased—Doxorubicin—kidney cancer	0.000307	0.00041	CcSEcCtD
Anagrelide—Malnutrition—Capecitabine—kidney cancer	0.000306	0.000409	CcSEcCtD
Anagrelide—Dehydration—Doxorubicin—kidney cancer	0.000305	0.000407	CcSEcCtD
Anagrelide—Oedema—Paclitaxel—kidney cancer	0.000305	0.000407	CcSEcCtD
Anagrelide—Body temperature increased—Vincristine—kidney cancer	0.000303	0.000405	CcSEcCtD
Anagrelide—Abdominal pain—Vincristine—kidney cancer	0.000303	0.000405	CcSEcCtD
Anagrelide—Liver function test abnormal—Doxorubicin—kidney cancer	0.000303	0.000404	CcSEcCtD
Anagrelide—Infection—Paclitaxel—kidney cancer	0.000303	0.000404	CcSEcCtD
Anagrelide—Flatulence—Capecitabine—kidney cancer	0.000302	0.000403	CcSEcCtD
Anagrelide—Dry skin—Doxorubicin—kidney cancer	0.0003	0.000401	CcSEcCtD
Anagrelide—CYP1A2—Estrogen Receptor Pathway—CYP1A1—kidney cancer	0.0003	0.0149	CbGpPWpGaD
Anagrelide—Dizziness—Sunitinib—kidney cancer	0.0003	0.000401	CcSEcCtD
Anagrelide—Feeling abnormal—Gemcitabine—kidney cancer	0.0003	0.0004	CcSEcCtD
Anagrelide—Shock—Paclitaxel—kidney cancer	0.0003	0.0004	CcSEcCtD
Anagrelide—Vomiting—Sorafenib—kidney cancer	0.000299	0.0004	CcSEcCtD
Anagrelide—Orthostatic hypotension—Doxorubicin—kidney cancer	0.000299	0.0004	CcSEcCtD
Anagrelide—Nervous system disorder—Paclitaxel—kidney cancer	0.000299	0.000399	CcSEcCtD
Anagrelide—Thrombocytopenia—Paclitaxel—kidney cancer	0.000298	0.000398	CcSEcCtD
Anagrelide—Tachycardia—Paclitaxel—kidney cancer	0.000297	0.000397	CcSEcCtD
Anagrelide—Rash—Sorafenib—kidney cancer	0.000297	0.000397	CcSEcCtD
Anagrelide—Dermatitis—Sorafenib—kidney cancer	0.000297	0.000397	CcSEcCtD
Anagrelide—Back pain—Capecitabine—kidney cancer	0.000296	0.000396	CcSEcCtD
Anagrelide—Skin disorder—Paclitaxel—kidney cancer	0.000296	0.000395	CcSEcCtD
Anagrelide—Headache—Sorafenib—kidney cancer	0.000295	0.000394	CcSEcCtD
Anagrelide—Muscle spasms—Capecitabine—kidney cancer	0.000294	0.000393	CcSEcCtD
Anagrelide—Hyperhidrosis—Paclitaxel—kidney cancer	0.000294	0.000393	CcSEcCtD
Anagrelide—Diarrhoea—Dactinomycin—kidney cancer	0.000294	0.000392	CcSEcCtD
Anagrelide—Anorexia—Paclitaxel—kidney cancer	0.00029	0.000388	CcSEcCtD
Anagrelide—Gastritis—Doxorubicin—kidney cancer	0.00029	0.000388	CcSEcCtD
Anagrelide—Vision blurred—Capecitabine—kidney cancer	0.000289	0.000386	CcSEcCtD
Anagrelide—Vomiting—Sunitinib—kidney cancer	0.000288	0.000385	CcSEcCtD
Anagrelide—Body temperature increased—Gemcitabine—kidney cancer	0.000288	0.000384	CcSEcCtD
Anagrelide—Rash—Sunitinib—kidney cancer	0.000286	0.000382	CcSEcCtD
Anagrelide—Dermatitis—Sunitinib—kidney cancer	0.000286	0.000382	CcSEcCtD
Anagrelide—Hypotension—Paclitaxel—kidney cancer	0.000285	0.00038	CcSEcCtD
Anagrelide—Ill-defined disorder—Capecitabine—kidney cancer	0.000284	0.00038	CcSEcCtD
Anagrelide—Headache—Sunitinib—kidney cancer	0.000284	0.000379	CcSEcCtD
Anagrelide—Dysphagia—Doxorubicin—kidney cancer	0.000283	0.000379	CcSEcCtD
Anagrelide—Influenza—Doxorubicin—kidney cancer	0.000283	0.000379	CcSEcCtD
Anagrelide—Asthma—Doxorubicin—kidney cancer	0.000283	0.000379	CcSEcCtD
Anagrelide—Anaemia—Capecitabine—kidney cancer	0.000283	0.000378	CcSEcCtD
Anagrelide—Nausea—Sorafenib—kidney cancer	0.00028	0.000374	CcSEcCtD
Anagrelide—Pancreatitis—Doxorubicin—kidney cancer	0.000278	0.000371	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000277	0.000371	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—L1CAM—kidney cancer	0.000277	0.0138	CbGpPWpGaD
Anagrelide—Malaise—Capecitabine—kidney cancer	0.000276	0.000369	CcSEcCtD
Anagrelide—Angina pectoris—Doxorubicin—kidney cancer	0.000276	0.000369	CcSEcCtD
Anagrelide—Insomnia—Paclitaxel—kidney cancer	0.000275	0.000368	CcSEcCtD
Anagrelide—Asthenia—Vincristine—kidney cancer	0.000275	0.000368	CcSEcCtD
Anagrelide—Syncope—Capecitabine—kidney cancer	0.000275	0.000367	CcSEcCtD
Anagrelide—Paraesthesia—Paclitaxel—kidney cancer	0.000273	0.000365	CcSEcCtD
Anagrelide—Vomiting—Dactinomycin—kidney cancer	0.000273	0.000365	CcSEcCtD
Anagrelide—Bronchitis—Doxorubicin—kidney cancer	0.000272	0.000364	CcSEcCtD
Anagrelide—Dyspnoea—Paclitaxel—kidney cancer	0.000271	0.000363	CcSEcCtD
Anagrelide—Somnolence—Paclitaxel—kidney cancer	0.000271	0.000362	CcSEcCtD
Anagrelide—Palpitations—Capecitabine—kidney cancer	0.000271	0.000362	CcSEcCtD
Anagrelide—Rash—Dactinomycin—kidney cancer	0.000271	0.000362	CcSEcCtD
Anagrelide—Nausea—Sunitinib—kidney cancer	0.000269	0.00036	CcSEcCtD
Anagrelide—Loss of consciousness—Capecitabine—kidney cancer	0.000269	0.00036	CcSEcCtD
Anagrelide—Pancytopenia—Doxorubicin—kidney cancer	0.000269	0.000359	CcSEcCtD
Anagrelide—Dyspepsia—Paclitaxel—kidney cancer	0.000268	0.000358	CcSEcCtD
Anagrelide—Cough—Capecitabine—kidney cancer	0.000267	0.000357	CcSEcCtD
Anagrelide—Dysuria—Doxorubicin—kidney cancer	0.000265	0.000354	CcSEcCtD
Anagrelide—Decreased appetite—Paclitaxel—kidney cancer	0.000265	0.000354	CcSEcCtD
Anagrelide—Hypertension—Capecitabine—kidney cancer	0.000264	0.000353	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000263	0.000351	CcSEcCtD
Anagrelide—Fatigue—Paclitaxel—kidney cancer	0.000263	0.000351	CcSEcCtD
Anagrelide—Diarrhoea—Vincristine—kidney cancer	0.000262	0.000351	CcSEcCtD
Anagrelide—Pollakiuria—Doxorubicin—kidney cancer	0.000262	0.00035	CcSEcCtD
Anagrelide—CYP1A2—Melatonin metabolism and effects—ACHE—kidney cancer	0.000262	0.013	CbGpPWpGaD
Anagrelide—Asthenia—Gemcitabine—kidney cancer	0.000261	0.000349	CcSEcCtD
Anagrelide—Myalgia—Capecitabine—kidney cancer	0.000261	0.000348	CcSEcCtD
Anagrelide—Chest pain—Capecitabine—kidney cancer	0.000261	0.000348	CcSEcCtD
Anagrelide—Arthralgia—Capecitabine—kidney cancer	0.000261	0.000348	CcSEcCtD
Anagrelide—Constipation—Paclitaxel—kidney cancer	0.00026	0.000348	CcSEcCtD
Anagrelide—Pain—Paclitaxel—kidney cancer	0.00026	0.000348	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000259	0.000346	CcSEcCtD
Anagrelide—Photosensitivity reaction—Doxorubicin—kidney cancer	0.000259	0.000345	CcSEcCtD
Anagrelide—Weight increased—Doxorubicin—kidney cancer	0.000258	0.000344	CcSEcCtD
Anagrelide—Discomfort—Capecitabine—kidney cancer	0.000258	0.000344	CcSEcCtD
Anagrelide—Pruritus—Gemcitabine—kidney cancer	0.000257	0.000344	CcSEcCtD
Anagrelide—Weight decreased—Doxorubicin—kidney cancer	0.000256	0.000342	CcSEcCtD
Anagrelide—Dry mouth—Capecitabine—kidney cancer	0.000255	0.000341	CcSEcCtD
Anagrelide—Nausea—Dactinomycin—kidney cancer	0.000255	0.000341	CcSEcCtD
Anagrelide—CYP1A2—Fatty Acid Omega Oxidation—CYP1A1—kidney cancer	0.000254	0.0126	CbGpPWpGaD
Anagrelide—Pneumonia—Doxorubicin—kidney cancer	0.000254	0.000339	CcSEcCtD
Anagrelide—Dizziness—Vincristine—kidney cancer	0.000254	0.000339	CcSEcCtD
Anagrelide—PDE3A—GPCR downstream signaling—OR4C13—kidney cancer	0.000253	0.0125	CbGpPWpGaD
Anagrelide—Confusional state—Capecitabine—kidney cancer	0.000252	0.000337	CcSEcCtD
Anagrelide—Feeling abnormal—Paclitaxel—kidney cancer	0.000251	0.000335	CcSEcCtD
Anagrelide—Oedema—Capecitabine—kidney cancer	0.00025	0.000334	CcSEcCtD
Anagrelide—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000249	0.000333	CcSEcCtD
Anagrelide—Diarrhoea—Gemcitabine—kidney cancer	0.000249	0.000333	CcSEcCtD
Anagrelide—Renal failure—Doxorubicin—kidney cancer	0.000248	0.000332	CcSEcCtD
Anagrelide—Infection—Capecitabine—kidney cancer	0.000248	0.000332	CcSEcCtD
Anagrelide—Shock—Capecitabine—kidney cancer	0.000246	0.000329	CcSEcCtD
Anagrelide—Conjunctivitis—Doxorubicin—kidney cancer	0.000245	0.000328	CcSEcCtD
Anagrelide—Urinary tract infection—Doxorubicin—kidney cancer	0.000245	0.000328	CcSEcCtD
Anagrelide—Nervous system disorder—Capecitabine—kidney cancer	0.000245	0.000327	CcSEcCtD
Anagrelide—Thrombocytopenia—Capecitabine—kidney cancer	0.000245	0.000327	CcSEcCtD
Anagrelide—CYP1A2—Estrogen metabolism—GSTM1—kidney cancer	0.000244	0.0121	CbGpPWpGaD
Anagrelide—Tachycardia—Capecitabine—kidney cancer	0.000244	0.000326	CcSEcCtD
Anagrelide—Vomiting—Vincristine—kidney cancer	0.000244	0.000326	CcSEcCtD
Anagrelide—Skin disorder—Capecitabine—kidney cancer	0.000243	0.000324	CcSEcCtD
Anagrelide—Sweating—Doxorubicin—kidney cancer	0.000242	0.000324	CcSEcCtD
Anagrelide—Urticaria—Paclitaxel—kidney cancer	0.000242	0.000323	CcSEcCtD
Anagrelide—Rash—Vincristine—kidney cancer	0.000242	0.000323	CcSEcCtD
Anagrelide—Hyperhidrosis—Capecitabine—kidney cancer	0.000242	0.000323	CcSEcCtD
Anagrelide—Dermatitis—Vincristine—kidney cancer	0.000242	0.000323	CcSEcCtD
Anagrelide—Haematuria—Doxorubicin—kidney cancer	0.000241	0.000322	CcSEcCtD
Anagrelide—Abdominal pain—Paclitaxel—kidney cancer	0.000241	0.000322	CcSEcCtD
Anagrelide—Body temperature increased—Paclitaxel—kidney cancer	0.000241	0.000322	CcSEcCtD
Anagrelide—Headache—Vincristine—kidney cancer	0.00024	0.000321	CcSEcCtD
Anagrelide—Hepatobiliary disease—Doxorubicin—kidney cancer	0.000239	0.000319	CcSEcCtD
Anagrelide—Epistaxis—Doxorubicin—kidney cancer	0.000238	0.000318	CcSEcCtD
Anagrelide—Anorexia—Capecitabine—kidney cancer	0.000238	0.000318	CcSEcCtD
Anagrelide—Sinusitis—Doxorubicin—kidney cancer	0.000237	0.000317	CcSEcCtD
Anagrelide—Hypotension—Capecitabine—kidney cancer	0.000233	0.000312	CcSEcCtD
Anagrelide—CYP1A2—Estrogen metabolism—CYP1A1—kidney cancer	0.000231	0.0115	CbGpPWpGaD
Anagrelide—Vomiting—Gemcitabine—kidney cancer	0.000231	0.000309	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—OR4C13—kidney cancer	0.000229	0.0114	CbGpPWpGaD
Anagrelide—Rash—Gemcitabine—kidney cancer	0.000229	0.000306	CcSEcCtD
Anagrelide—Dermatitis—Gemcitabine—kidney cancer	0.000229	0.000306	CcSEcCtD
Anagrelide—Haemoglobin—Doxorubicin—kidney cancer	0.000228	0.000305	CcSEcCtD
Anagrelide—Headache—Gemcitabine—kidney cancer	0.000228	0.000304	CcSEcCtD
Anagrelide—Nausea—Vincristine—kidney cancer	0.000228	0.000304	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.000228	0.000304	CcSEcCtD
Anagrelide—Rhinitis—Doxorubicin—kidney cancer	0.000227	0.000304	CcSEcCtD
Anagrelide—Haemorrhage—Doxorubicin—kidney cancer	0.000227	0.000303	CcSEcCtD
Anagrelide—Hepatitis—Doxorubicin—kidney cancer	0.000227	0.000303	CcSEcCtD
Anagrelide—Insomnia—Capecitabine—kidney cancer	0.000226	0.000302	CcSEcCtD
Anagrelide—Hypoaesthesia—Doxorubicin—kidney cancer	0.000226	0.000301	CcSEcCtD
Anagrelide—Pharyngitis—Doxorubicin—kidney cancer	0.000225	0.000301	CcSEcCtD
Anagrelide—Paraesthesia—Capecitabine—kidney cancer	0.000224	0.0003	CcSEcCtD
Anagrelide—Urinary tract disorder—Doxorubicin—kidney cancer	0.000224	0.000299	CcSEcCtD
Anagrelide—Oedema peripheral—Doxorubicin—kidney cancer	0.000223	0.000298	CcSEcCtD
Anagrelide—Connective tissue disorder—Doxorubicin—kidney cancer	0.000223	0.000298	CcSEcCtD
Anagrelide—Dyspnoea—Capecitabine—kidney cancer	0.000223	0.000298	CcSEcCtD
Anagrelide—Urethral disorder—Doxorubicin—kidney cancer	0.000222	0.000297	CcSEcCtD
Anagrelide—Dyspepsia—Capecitabine—kidney cancer	0.00022	0.000294	CcSEcCtD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUND—kidney cancer	0.000219	0.0109	CbGpPWpGaD
Anagrelide—Visual impairment—Doxorubicin—kidney cancer	0.000218	0.000292	CcSEcCtD
Anagrelide—Asthenia—Paclitaxel—kidney cancer	0.000218	0.000292	CcSEcCtD
Anagrelide—Decreased appetite—Capecitabine—kidney cancer	0.000217	0.00029	CcSEcCtD
Anagrelide—Nausea—Gemcitabine—kidney cancer	0.000216	0.000289	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000216	0.000288	CcSEcCtD
Anagrelide—Fatigue—Capecitabine—kidney cancer	0.000215	0.000288	CcSEcCtD
Anagrelide—Pruritus—Paclitaxel—kidney cancer	0.000215	0.000288	CcSEcCtD
Anagrelide—Constipation—Capecitabine—kidney cancer	0.000214	0.000286	CcSEcCtD
Anagrelide—Pain—Capecitabine—kidney cancer	0.000214	0.000286	CcSEcCtD
Anagrelide—CYP1A2—Xenobiotics—CYP1A1—kidney cancer	0.000213	0.0106	CbGpPWpGaD
Anagrelide—Eye disorder—Doxorubicin—kidney cancer	0.000212	0.000283	CcSEcCtD
Anagrelide—Tinnitus—Doxorubicin—kidney cancer	0.000211	0.000282	CcSEcCtD
Anagrelide—Cardiac disorder—Doxorubicin—kidney cancer	0.00021	0.000281	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—ANXA2—kidney cancer	0.00021	0.0104	CbGpPWpGaD
Anagrelide—Diarrhoea—Paclitaxel—kidney cancer	0.000208	0.000278	CcSEcCtD
Anagrelide—Feeling abnormal—Capecitabine—kidney cancer	0.000206	0.000275	CcSEcCtD
Anagrelide—CYP1A2—Tamoxifen metabolism—CYP1A1—kidney cancer	0.000204	0.0101	CbGpPWpGaD
Anagrelide—Gastrointestinal pain—Capecitabine—kidney cancer	0.000204	0.000273	CcSEcCtD
Anagrelide—Mediastinal disorder—Doxorubicin—kidney cancer	0.000204	0.000273	CcSEcCtD
Anagrelide—Chills—Doxorubicin—kidney cancer	0.000203	0.000272	CcSEcCtD
Anagrelide—Arrhythmia—Doxorubicin—kidney cancer	0.000203	0.000271	CcSEcCtD
Anagrelide—CYP1A2—Phase 1 - Functionalization of compounds—ALDH1A1—kidney cancer	0.000202	0.01	CbGpPWpGaD
Anagrelide—Dizziness—Paclitaxel—kidney cancer	0.000201	0.000269	CcSEcCtD
Anagrelide—Alopecia—Doxorubicin—kidney cancer	0.0002	0.000268	CcSEcCtD
Anagrelide—Urticaria—Capecitabine—kidney cancer	0.000199	0.000265	CcSEcCtD
Anagrelide—Body temperature increased—Capecitabine—kidney cancer	0.000198	0.000264	CcSEcCtD
Anagrelide—Abdominal pain—Capecitabine—kidney cancer	0.000198	0.000264	CcSEcCtD
Anagrelide—Malnutrition—Doxorubicin—kidney cancer	0.000197	0.000264	CcSEcCtD
Anagrelide—CYP1A2—Biological oxidations—ACY1—kidney cancer	0.000196	0.0097	CbGpPWpGaD
Anagrelide—Flatulence—Doxorubicin—kidney cancer	0.000194	0.00026	CcSEcCtD
Anagrelide—Tension—Doxorubicin—kidney cancer	0.000194	0.000259	CcSEcCtD
Anagrelide—Vomiting—Paclitaxel—kidney cancer	0.000194	0.000259	CcSEcCtD
Anagrelide—Rash—Paclitaxel—kidney cancer	0.000192	0.000257	CcSEcCtD
Anagrelide—Dermatitis—Paclitaxel—kidney cancer	0.000192	0.000256	CcSEcCtD
Anagrelide—Nervousness—Doxorubicin—kidney cancer	0.000192	0.000256	CcSEcCtD
Anagrelide—Back pain—Doxorubicin—kidney cancer	0.000191	0.000255	CcSEcCtD
Anagrelide—Headache—Paclitaxel—kidney cancer	0.000191	0.000255	CcSEcCtD
Anagrelide—Muscle spasms—Doxorubicin—kidney cancer	0.00019	0.000254	CcSEcCtD
Anagrelide—Vision blurred—Doxorubicin—kidney cancer	0.000186	0.000249	CcSEcCtD
Anagrelide—Ill-defined disorder—Doxorubicin—kidney cancer	0.000183	0.000245	CcSEcCtD
Anagrelide—Anaemia—Doxorubicin—kidney cancer	0.000182	0.000244	CcSEcCtD
Anagrelide—Nausea—Paclitaxel—kidney cancer	0.000181	0.000242	CcSEcCtD
Anagrelide—Asthenia—Capecitabine—kidney cancer	0.000179	0.00024	CcSEcCtD
Anagrelide—PDE3A—G alpha (s) signalling events—POMC—kidney cancer	0.000179	0.00886	CbGpPWpGaD
Anagrelide—Malaise—Doxorubicin—kidney cancer	0.000178	0.000238	CcSEcCtD
Anagrelide—Syncope—Doxorubicin—kidney cancer	0.000177	0.000237	CcSEcCtD
Anagrelide—Pruritus—Capecitabine—kidney cancer	0.000177	0.000236	CcSEcCtD
Anagrelide—Palpitations—Doxorubicin—kidney cancer	0.000174	0.000233	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—KCNMA1—kidney cancer	0.000174	0.00864	CbGpPWpGaD
Anagrelide—Loss of consciousness—Doxorubicin—kidney cancer	0.000173	0.000232	CcSEcCtD
Anagrelide—Cough—Doxorubicin—kidney cancer	0.000172	0.00023	CcSEcCtD
Anagrelide—Convulsion—Doxorubicin—kidney cancer	0.000171	0.000229	CcSEcCtD
Anagrelide—Diarrhoea—Capecitabine—kidney cancer	0.000171	0.000228	CcSEcCtD
Anagrelide—Hypertension—Doxorubicin—kidney cancer	0.00017	0.000228	CcSEcCtD
Anagrelide—Chest pain—Doxorubicin—kidney cancer	0.000168	0.000225	CcSEcCtD
Anagrelide—Arthralgia—Doxorubicin—kidney cancer	0.000168	0.000225	CcSEcCtD
Anagrelide—Myalgia—Doxorubicin—kidney cancer	0.000168	0.000225	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.000167	0.000223	CcSEcCtD
Anagrelide—Discomfort—Doxorubicin—kidney cancer	0.000166	0.000222	CcSEcCtD
Anagrelide—Dizziness—Capecitabine—kidney cancer	0.000165	0.000221	CcSEcCtD
Anagrelide—Dry mouth—Doxorubicin—kidney cancer	0.000164	0.00022	CcSEcCtD
Anagrelide—Confusional state—Doxorubicin—kidney cancer	0.000162	0.000217	CcSEcCtD
Anagrelide—Oedema—Doxorubicin—kidney cancer	0.000161	0.000215	CcSEcCtD
Anagrelide—CYP1A2—Estrogen Receptor Pathway—JUN—kidney cancer	0.000161	0.00799	CbGpPWpGaD
Anagrelide—Infection—Doxorubicin—kidney cancer	0.00016	0.000214	CcSEcCtD
Anagrelide—Vomiting—Capecitabine—kidney cancer	0.000159	0.000212	CcSEcCtD
Anagrelide—CYP1A2—Arachidonic acid metabolism—PTGS1—kidney cancer	0.000159	0.00787	CbGpPWpGaD
Anagrelide—Shock—Doxorubicin—kidney cancer	0.000158	0.000212	CcSEcCtD
Anagrelide—Nervous system disorder—Doxorubicin—kidney cancer	0.000158	0.000211	CcSEcCtD
Anagrelide—CYP1A2—Melatonin metabolism and effects—CYP1A1—kidney cancer	0.000158	0.00784	CbGpPWpGaD
Anagrelide—Thrombocytopenia—Doxorubicin—kidney cancer	0.000158	0.000211	CcSEcCtD
Anagrelide—Rash—Capecitabine—kidney cancer	0.000158	0.000211	CcSEcCtD
Anagrelide—Dermatitis—Capecitabine—kidney cancer	0.000157	0.00021	CcSEcCtD
Anagrelide—Tachycardia—Doxorubicin—kidney cancer	0.000157	0.00021	CcSEcCtD
Anagrelide—Headache—Capecitabine—kidney cancer	0.000157	0.000209	CcSEcCtD
Anagrelide—Skin disorder—Doxorubicin—kidney cancer	0.000156	0.000209	CcSEcCtD
Anagrelide—Hyperhidrosis—Doxorubicin—kidney cancer	0.000156	0.000208	CcSEcCtD
Anagrelide—Anorexia—Doxorubicin—kidney cancer	0.000154	0.000205	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—GRB7—kidney cancer	0.000152	0.00754	CbGpPWpGaD
Anagrelide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—kidney cancer	0.000151	0.0075	CbGpPWpGaD
Anagrelide—Hypotension—Doxorubicin—kidney cancer	0.000151	0.000201	CcSEcCtD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUNB—kidney cancer	0.000149	0.0074	CbGpPWpGaD
Anagrelide—Nausea—Capecitabine—kidney cancer	0.000148	0.000198	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Doxorubicin—kidney cancer	0.000147	0.000196	CcSEcCtD
Anagrelide—Insomnia—Doxorubicin—kidney cancer	0.000146	0.000195	CcSEcCtD
Anagrelide—Paraesthesia—Doxorubicin—kidney cancer	0.000145	0.000193	CcSEcCtD
Anagrelide—Dyspnoea—Doxorubicin—kidney cancer	0.000144	0.000192	CcSEcCtD
Anagrelide—Somnolence—Doxorubicin—kidney cancer	0.000143	0.000191	CcSEcCtD
Anagrelide—Dyspepsia—Doxorubicin—kidney cancer	0.000142	0.000189	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—ITPR2—kidney cancer	0.000141	0.00701	CbGpPWpGaD
Anagrelide—Decreased appetite—Doxorubicin—kidney cancer	0.00014	0.000187	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.000139	0.000186	CcSEcCtD
Anagrelide—Fatigue—Doxorubicin—kidney cancer	0.000139	0.000186	CcSEcCtD
Anagrelide—Constipation—Doxorubicin—kidney cancer	0.000138	0.000184	CcSEcCtD
Anagrelide—Pain—Doxorubicin—kidney cancer	0.000138	0.000184	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—OR4C13—kidney cancer	0.000136	0.00673	CbGpPWpGaD
Anagrelide—Feeling abnormal—Doxorubicin—kidney cancer	0.000133	0.000177	CcSEcCtD
Anagrelide—Gastrointestinal pain—Doxorubicin—kidney cancer	0.000132	0.000176	CcSEcCtD
Anagrelide—Urticaria—Doxorubicin—kidney cancer	0.000128	0.000171	CcSEcCtD
Anagrelide—Abdominal pain—Doxorubicin—kidney cancer	0.000127	0.00017	CcSEcCtD
Anagrelide—Body temperature increased—Doxorubicin—kidney cancer	0.000127	0.00017	CcSEcCtD
Anagrelide—Asthenia—Doxorubicin—kidney cancer	0.000116	0.000154	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—LATS1—kidney cancer	0.000115	0.00572	CbGpPWpGaD
Anagrelide—Pruritus—Doxorubicin—kidney cancer	0.000114	0.000152	CcSEcCtD
Anagrelide—CYP1A2—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	0.000111	0.00551	CbGpPWpGaD
Anagrelide—Diarrhoea—Doxorubicin—kidney cancer	0.00011	0.000147	CcSEcCtD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—CYP1A1—kidney cancer	0.000109	0.00542	CbGpPWpGaD
Anagrelide—CYP1A2—Tryptophan metabolism—CYP1A1—kidney cancer	0.000109	0.00542	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1A1—kidney cancer	0.000109	0.00542	CbGpPWpGaD
Anagrelide—CYP1A2—Phase II conjugation—GSTT1—kidney cancer	0.000108	0.00534	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—ALDH1A1—kidney cancer	0.000107	0.00532	CbGpPWpGaD
Anagrelide—Dizziness—Doxorubicin—kidney cancer	0.000107	0.000142	CcSEcCtD
Anagrelide—PDE3A—GPCR downstream signaling—AKAP13—kidney cancer	0.000105	0.00521	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—IFNA1—kidney cancer	0.000104	0.00514	CbGpPWpGaD
Anagrelide—Vomiting—Doxorubicin—kidney cancer	0.000102	0.000137	CcSEcCtD
Anagrelide—CYP1A2—Arachidonic acid metabolism—CYP1A1—kidney cancer	0.000102	0.00507	CbGpPWpGaD
Anagrelide—Rash—Doxorubicin—kidney cancer	0.000102	0.000136	CcSEcCtD
Anagrelide—Dermatitis—Doxorubicin—kidney cancer	0.000101	0.000136	CcSEcCtD
Anagrelide—Headache—Doxorubicin—kidney cancer	0.000101	0.000135	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—AMER1—kidney cancer	9.8e-05	0.00486	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—IFNA2—kidney cancer	9.65e-05	0.00479	CbGpPWpGaD
Anagrelide—Nausea—Doxorubicin—kidney cancer	9.57e-05	0.000128	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—AKAP13—kidney cancer	9.53e-05	0.00473	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—ITPR2—kidney cancer	8.92e-05	0.00443	CbGpPWpGaD
Anagrelide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	8.83e-05	0.00438	CbGpPWpGaD
Anagrelide—CYP1A2—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	8.71e-05	0.00432	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—IGF2—kidney cancer	8.68e-05	0.00431	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—GPC3—kidney cancer	8.21e-05	0.00408	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CER1—kidney cancer	8.21e-05	0.00408	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—ITPR2—kidney cancer	8.1e-05	0.00402	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—ANXA1—kidney cancer	7.48e-05	0.00371	CbGpPWpGaD
Anagrelide—CYP1A2—Phase II conjugation—GSTP1—kidney cancer	7.46e-05	0.0037	CbGpPWpGaD
Anagrelide—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	7.16e-05	0.00355	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—SFRP2—kidney cancer	6.98e-05	0.00347	CbGpPWpGaD
Anagrelide—CYP1A2—Phase II conjugation—GSTM1—kidney cancer	6.86e-05	0.0034	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—ANXA1—kidney cancer	6.79e-05	0.00337	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—kidney cancer	6.71e-05	0.00333	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—RELA—kidney cancer	6.68e-05	0.00332	CbGpPWpGaD
Anagrelide—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	6.58e-05	0.00327	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—kidney cancer	6.49e-05	0.00322	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—GSTT1—kidney cancer	6.3e-05	0.00312	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—kidney cancer	6.15e-05	0.00305	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—kidney cancer	6.15e-05	0.00305	CbGpPWpGaD
Anagrelide—CYP1A2—Arachidonic acid metabolism—PTGS2—kidney cancer	6.07e-05	0.00301	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—kidney cancer	6.02e-05	0.00299	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—PTGS1—kidney cancer	5.9e-05	0.00293	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—kidney cancer	5.86e-05	0.00291	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CASP2—kidney cancer	5.63e-05	0.00279	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—AKAP13—kidney cancer	5.63e-05	0.00279	CbGpPWpGaD
Anagrelide—CYP1A2—Phase 1 - Functionalization of compounds—POMC—kidney cancer	5.34e-05	0.00265	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—GLIPR1—kidney cancer	5.21e-05	0.00258	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—GRB7—kidney cancer	5.15e-05	0.00255	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—kidney cancer	5.12e-05	0.00254	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ITPR2—kidney cancer	4.79e-05	0.00238	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—RAF1—kidney cancer	4.78e-05	0.00237	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—kidney cancer	4.71e-05	0.00234	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—kidney cancer	4.6e-05	0.00228	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—GSTP1—kidney cancer	4.36e-05	0.00217	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—kidney cancer	4.35e-05	0.00216	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CTNNA1—kidney cancer	4.34e-05	0.00215	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—EIF4EBP1—kidney cancer	4.31e-05	0.00214	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—HSPB1—kidney cancer	4.31e-05	0.00214	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—GSTP1—kidney cancer	4.3e-05	0.00214	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—IL2—kidney cancer	4.29e-05	0.00213	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TSC1—kidney cancer	4.01e-05	0.00199	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PSMD7—kidney cancer	4.01e-05	0.00199	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ANXA1—kidney cancer	4.01e-05	0.00199	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—GSTM1—kidney cancer	4.01e-05	0.00199	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—GSTM1—kidney cancer	3.96e-05	0.00196	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—FLT1—kidney cancer	3.88e-05	0.00193	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—CYP1A1—kidney cancer	3.8e-05	0.00189	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—CYP1A1—kidney cancer	3.75e-05	0.00186	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—POMC—kidney cancer	3.66e-05	0.00182	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—VEGFA—kidney cancer	3.64e-05	0.00181	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PAK1—kidney cancer	3.6e-05	0.00179	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—JUNB—kidney cancer	3.6e-05	0.00179	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—MAPK3—kidney cancer	3.45e-05	0.00171	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ACY1—kidney cancer	3.34e-05	0.00166	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—POMC—kidney cancer	3.33e-05	0.00165	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—MAPK1—kidney cancer	3.28e-05	0.00163	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—KRAS—kidney cancer	3.1e-05	0.00154	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IGF2—kidney cancer	2.94e-05	0.00146	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CDKN2B—kidney cancer	2.93e-05	0.00145	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	2.85e-05	0.00142	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IGF1R—kidney cancer	2.85e-05	0.00141	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—PIK3CA—kidney cancer	2.84e-05	0.00141	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PDHB—kidney cancer	2.84e-05	0.00141	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—POMC—kidney cancer	2.83e-05	0.00141	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—TP53—kidney cancer	2.75e-05	0.00137	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—RAF1—kidney cancer	2.74e-05	0.00136	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—IL2—kidney cancer	2.71e-05	0.00134	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CCBL1—kidney cancer	2.67e-05	0.00133	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—IL2—kidney cancer	2.46e-05	0.00122	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	2.42e-05	0.0012	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—HIF1A—kidney cancer	2.34e-05	0.00116	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TSC2—kidney cancer	2.34e-05	0.00116	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PPAT—kidney cancer	2.32e-05	0.00115	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GLIPR1—kidney cancer	2.32e-05	0.00115	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	2.29e-05	0.00114	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	2.27e-05	0.00112	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—KDR—kidney cancer	2.24e-05	0.00111	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—APRT—kidney cancer	2.16e-05	0.00107	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—FH—kidney cancer	2.16e-05	0.00107	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	2.11e-05	0.00105	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—KIT—kidney cancer	2.06e-05	0.00102	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—APC—kidney cancer	2.06e-05	0.00102	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GPC3—kidney cancer	2.03e-05	0.00101	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—MAPK3—kidney cancer	1.98e-05	0.000981	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CA2—kidney cancer	1.97e-05	0.000978	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—POMC—kidney cancer	1.97e-05	0.000975	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—BRAF—kidney cancer	1.94e-05	0.000963	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALAD—kidney cancer	1.92e-05	0.000953	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—MAPK1—kidney cancer	1.88e-05	0.000934	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ST3GAL2—kidney cancer	1.87e-05	0.00093	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALDH1A1—kidney cancer	1.83e-05	0.000909	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—PIK3CA—kidney cancer	1.8e-05	0.000892	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—KRAS—kidney cancer	1.78e-05	0.000882	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PGK1—kidney cancer	1.76e-05	0.000872	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SLC5A3—kidney cancer	1.76e-05	0.000872	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—LDHB—kidney cancer	1.72e-05	0.000855	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PIK3CA—kidney cancer	1.63e-05	0.00081	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—RAF1—kidney cancer	1.62e-05	0.000804	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—RELA—kidney cancer	1.61e-05	0.0008	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ERBB2—kidney cancer	1.6e-05	0.000795	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MTOR—kidney cancer	1.58e-05	0.000785	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CA9—kidney cancer	1.49e-05	0.000741	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CDKN1B—kidney cancer	1.48e-05	0.000737	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	1.46e-05	0.000724	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IL2—kidney cancer	1.45e-05	0.000721	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CCND1—kidney cancer	1.42e-05	0.000703	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—JUN—kidney cancer	1.41e-05	0.000701	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CTNNB1—kidney cancer	1.4e-05	0.000696	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PTEN—kidney cancer	1.37e-05	0.000678	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CRABP1—kidney cancer	1.27e-05	0.00063	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—VEGFA—kidney cancer	1.23e-05	0.000613	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ITPR2—kidney cancer	1.18e-05	0.000586	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MAPK3—kidney cancer	1.17e-05	0.00058	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MYC—kidney cancer	1.14e-05	0.000564	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MAPK1—kidney cancer	1.11e-05	0.000551	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.09e-05	0.00054	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ACHE—kidney cancer	1.08e-05	0.000534	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTT1—kidney cancer	1.08e-05	0.000534	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—KRAS—kidney cancer	1.05e-05	0.000521	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SCARB1—kidney cancer	1.02e-05	0.000506	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PTGS1—kidney cancer	1.01e-05	0.000501	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PSMD7—kidney cancer	9.89e-06	0.000491	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PIK3CA—kidney cancer	9.64e-06	0.000479	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—BCHE—kidney cancer	9.38e-06	0.000465	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TP53—kidney cancer	9.33e-06	0.000463	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SLC5A5—kidney cancer	9.27e-06	0.00046	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SLC2A1—kidney cancer	8.95e-06	0.000444	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	8.68e-06	0.000431	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	7.57e-06	0.000376	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTP1—kidney cancer	7.46e-06	0.00037	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ABCB1—kidney cancer	7.06e-06	0.000351	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTM1—kidney cancer	6.86e-06	0.00034	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP1A1—kidney cancer	6.5e-06	0.000323	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	5.34e-06	0.000265	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—POMC—kidney cancer	4.85e-06	0.000241	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PTGS2—kidney cancer	3.87e-06	0.000192	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PTEN—kidney cancer	3.37e-06	0.000167	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PIK3CA—kidney cancer	2.38e-06	0.000118	CbGpPWpGaD
